Adicet Bio, Inc. (ACET)

$1.37

+0.13

(+10.48%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $1.22
    $1.38
    $1.37
    downward going graph

    10.95%

    Downside

    Day's Volatility :11.27%

    Upside

    0.36%

    downward going graph
  • $1.05
    $3.77
    $1.37
    downward going graph

    23.36%

    Downside

    52 Weeks Volatility :72.15%

    Upside

    63.66%

    downward going graph

Returns

PeriodAdicet Bio, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-34.76%
5.3%
0.0%
6 Months
-45.42%
6.3%
0.0%
1 Year
-45.42%
9.2%
0.0%
3 Years
-83.15%
13.1%
-19.9%

Highlights

Market Capitalization
101.9M
Book Value
$3.15
Earnings Per Share (EPS)
-2.94
PEG Ratio
0.82
Wall Street Target Price
9.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.2%
Return On Equity TTM
-53.25%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
25.0M
EBITDA
-123.6M
Diluted Eps TTM
-2.94
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.45
EPS Estimate Next Year
-1.58
EPS Estimate Current Quarter
-0.39
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Adicet Bio, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
3
3
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 556.93%

Current $1.37
Target $9.00

Technicals Summary

Sell

Neutral

Buy

Adicet Bio, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adicet Bio, Inc.
Adicet Bio, Inc.
-8.67%
-45.42%
-45.42%
-83.15%
-88.03%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adicet Bio, Inc.
Adicet Bio, Inc.
NA
NA
0.82
-1.45
-0.53
-0.27
NA
3.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adicet Bio, Inc.
Adicet Bio, Inc.
Buy
$101.9M
-88.03%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Adicet Bio, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 114.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 276.6%

Institutional Holdings

  • Orbimed Advisors, LLC

    13.93%
  • RA Capital Management, LLC

    9.18%
  • TANG CAPITAL MANAGEMENT LLC

    7.80%
  • Balyasny Asset Management LLC

    7.52%
  • RTW INVESTMENTS, LLC

    5.03%
  • Millennium Management LLC

    5.00%

Company Information

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v

Organization
Adicet Bio, Inc.
Employees
143
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Industry
Distribution Services

FAQs